Nerve ultrasound in people with Friedreich ataxia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center observational project at CHU de Nice using routine peripheral nerve ultrasound exams performed between December 2025 and April 2026. It includes adults aged 18–70 with a genetically confirmed diagnosis of Friedreich ataxia who are followed at the Neurogenetics Competence Centre. Sonographers record nerve size and appearance in the upper and lower limbs and compare findings to expected normal ranges. No experimental treatments are given; the aim is to better describe peripheral nerve involvement to inform clinical care and future research.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged between 18 and 70 years.
* Genetically confirmed diagnosis of Friedreich's Ataxia.
* Followed at the Neurogenetics Competence Centre, CHU Nice.
* Have undergone peripheral nerve ultrasound between December 2025 and April 2026.

Exclusion Criteria:

* Patients for whom peripheral nerve ultrasound data is unavailable.

Where it's running

• CHU de Nice
  Nice, Alpes Maritimes, France Recruiting

Study contacts

• Study coordinator: Andra Ezaru
• Email: ezaru.a@chu-nice.fr
• Phone: 07 80 65 10 81

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nomlabofusp by injection for Friedreich's Ataxia: efficacy and safety

  This study tests whether subcutaneous nomlabofusp helps adults and children with Friedreich's Ataxia compared with placebo.

  Recruiting at 3 sites Phase 3 Larimar Therapeutics, Inc. · Tampa, Florida and 3 other locations · NCT07778836

• LX2006 Gene Therapy for Friedreich Ataxia Cardiomyopathy (FA-CM)

  A Phase 2 study tests LX2006 gene therapy in people with Friedreich ataxia who also have cardiomyopathy to see if it helps heart function and safety.

  Recruiting Phase 2 Lexeo Therapeutics · Tampa, Florida · NCT07721025

• Omaveloxolone for swallowing problems in French people with Friedreich's ataxia

  This project will test whether omaveloxolone (SKYCLARYS) improves swallowing in French people aged 16 and older with genetically confirmed Friedreich's ataxia who have used the drug for at least six months.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice, Alpes Maritimes · NCT07013292

• Testing DT-216P2 in patients with Friedreich's Ataxia

  This study is testing a new drug called DT-216P2 in adults with Friedreich's Ataxia to see how safe it is and how well it works in their bodies.

  Recruiting at 3 sites Phase 1/2 Design Therapeutics, Inc. · Sydney, New South Wales and 2 other locations · NCT06874010

• Clinical course of cardiomyopathy in people with Friedreich ataxia

  This study follows people with Friedreich ataxia who have cardiomyopathy to see how their heart disease changes over time and to identify who may later be eligible for a gene therapy study.

  Recruiting at 18 sites Lexeo Therapeutics · La Jolla, California and 18 other locations · NCT06865482

• Health effects of omaveloxolone taken during pregnancy or breastfeeding in people with Friedreich's Ataxia

  See if taking BIIB141 (omaveloxolone) during pregnancy or while breastfeeding affects the health of people with Friedreich's Ataxia and their babies.

  Recruiting Biogen · Morrisville, North Carolina · NCT06628687

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.